# Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

> **NCT05758896** · PHASE2 · RECRUITING · sponsor: **Aptabio Therapeutics, Inc.** · enrollment: 280 (estimated)

## Conditions studied

- Contrast Induced Acute Kidney Injury

## Interventions

- **DRUG:** Isuzinaxib (APX-115)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05758896
- **Lead sponsor:** Aptabio Therapeutics, Inc.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-27
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05758896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05758896, "Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05758896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*